Agenus reports q4 and year-end 2024 results; strategic operational improvements and significant cost reductions enhance sustainability of promising bot/bal program

Lexington, mass.--(business wire)--agenus inc. (“agenus” or the “company”) (nasdaq: agen), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading bot/bal program. "in line with our strategic objectives, we significantly reduced our annualized operational burn rate. we anticipat.
AGEN Ratings Summary
AGEN Quant Ranking